Brady James Aloysius 4

What Happened
Brady James Aloysius, a director of Xeris Biopharma Holdings, Inc. (XERS), disposed of 10,834 shares on March 30, 2026. The shares were sold at a weighted-average price of $5.54 per share, for gross proceeds of approximately $60,036. The Form 4 lists the transaction as an open-market or private sale (code S).

Key Details

• Transaction date: 2026-03-30; Form 4 filed 2026-04-01 (filed within the required reporting window).
• Transaction type: Sale (S) — open market/private sale.
• Shares sold: 10,834; weighted-average price: $5.54; gross proceeds: ~$60,036.
• Price range: shares were sold in multiple transactions at prices from $5.29 to $5.63 (Footnote F2). The reporting person will provide per-price breakdown upon request.
• Footnote F1: Transaction effected pursuant to a Rule 10b5-1 trading plan (pre‑planned sales).
• Shares owned after the transaction: not disclosed in this filing.

Context
A Rule 10b5-1 plan indicates these trades were pre‑arranged and may be routine, so they do not necessarily signal the insider’s current view on the company. This was a straightforward sale (not an option exercise, gift, or award).